43% Upside Seen For Dova Pharma Following Competitor Product's Poor Results
September 26, 2017 at 09:10 AM EDT
Analysts at Leerink turned bullish on Dova Pharmaceuticals Inc (NASDAQ: DOVA) after a competitor to the clinical-stage pharmaceutical ...